Validating the Potential of VGT-309 in Solid Tumors
In Phase 1 and 2 clinical studies, VGT-309 was shown to be safe and well- tolerated at all doses studied. Other important clinical highlights included:
VGT-309 imaging identified visually non-discernable, non-palpable tumors in real time.
VGT-309 visualization showed an unexpected positive lymph node that the surgeon removed and subsequently confirmed as containing malignancy.
VGT-309 tumor visualization allowed for preservation of healthy tissue following prior lung cancer surgery.
VGT-309 imaging identified a colorectal cancer tumor that had metastasized to a patient’s lung, was not visible on PET and CT imaging, and the surgeon would have otherwise missed.
Phase 1 and and 2 Clinical Studies Have Yielded Compelling Data
Results suggest VGT-309 is safe and well-tolerated, and labels human lung tumors during resection surgeries.
Phase 2 multi-center safety and efficacy study for cancer in the lung (NCT06145048)
Phase 2 clinical study in lung cancer surgery ongoing (NCT05400226)
Phase 2 dose-ranging study in lung cancer surgery ongoing (ACTRN12621000301864)
Phase 1 clinical study for safety in healthy human volunteers completed (ACTRN12620000948998)
1. Scientific manuscript in preparation